ClinicalTrials.gg
Enrolling by invitationNCT07218003Updated Jun 11, 2026

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

A Phase 1 interventional study of RNDO-564 and Pembrolizumab in Non Small Cell Lung Cancer, Cervical Cancer and Head and Neck Squamous Cell Cancer, sponsored by Rondo Therapeutics. Enrolling by invitation at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Rondo Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
149
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
804th of 2,995
149 · median 56
Started
2025
with 148 others
Phase 1
927 of 3,368
134 open now
Primary completion
2029-02
later than 706 of 892 live
Registered
3,231st of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 804th largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 149 that started in 2025, is one of 927 in phase 1, reaches primary completion later than 706 of the 892 other live ones, and was the 3,231st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body.

The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured.

Participants will take RNDO-564 weekly on Days 1, 8 and 15 of a 21 day cycle. Participants in the combination arms will take RNDO-564 as described with pembrolizumab every 3 weeks.

Read the detailed description

The study will consist of four stages: 1) single agent dose escalation, 2) single agent dose optimization, 3) combination dose escalation and 4) combination dose optimization.

Stages 1 and 3 are dose escalation to investigate the safety and tolerability of increasing doses of RNDO-564 as a single agent and in combination with standard pembrolizumab treatment. Participants will be enrolled who have one of the following advanced solid tumors associated with Nectin-4: locally advanced/metastatic urothelial cancer (la/m UC), cervical cancer (CC), head and neck cancer (HNSCC), esophageal cancer (EC), gastric (GC) and gastroesophageal junction cancer (GEJ), triple negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). The cancer must not have responded well to previous cancer treatments. Stages 1, and 3 will be non-randomized.

Stages 2 (i.e., RNDO-564 single agent) and 4 (i.e., RNDO-564 in combination with pembrolizumab) are dose optimization and proof-of-concept stages to further investigate the safety and tolerability of at least 2 doses of RNDO-564 as a single agent and in combination with standard pembrolizumab treatment, and to investigate preliminary anti-tumor activity. Stages 2 and 4 will enroll participants with advanced urothelial cancer only. The cancer must not have responded well to previous cancer treatments. Participants will be randomized (1:1) into one of two arms which will evaluate two dose levels (as selected from Stages 1 and 3).

The study consists of a screening period, a treatment period, an end of treatment visit, a safety follow-up visit, and 60 and 90 days telephone follow-up after ending treatment. The treatment period will last for a maximum of 2 years.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Cervical Cancer
  • Head and Neck Squamous Cell Cancer
  • Triple Negative Breast Cancer (TNBC)
  • Urothelial Carcinoma Bladder
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Esophageal Squamous Cell Cancer
  • Gastric Cancer
  • Cancer
  • Solid Tumors (Phase 1)

Keywords

  • RNDO-564-001
  • bladder cancer
  • bispecific antibody
  • solid tumors
  • Nectin-4
  • dose escalation
  • Phase 1/1b
  • CD28 x Nectin-4 bispecific
  • T-cell engager
  • CD28 costimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) Eligible tumor types: Histologic documentation of incurable, locally advanced or solid tumors for which established standard systemic therapies are no longer effective (participant must have experienced progressive disease), are not tolerated, or in the opinion of the Investigator have been considered ineligible for a particular form of standard therapy on medical grounds or have been declined by the participant, with these tumor subtypes:

A. Monotherapy and Combination Dose Escalation Arms:

  • RR la/mUC: Participants with urothelial cancer (transitional cell) with squamous differentiation or mixed cell types are eligible. Participants with upper tract disease, e.g., involving ureters, or renal pelvis, are eligible. Participants may have had up to 2 prior monomethyl auristatin E (MMAE)-containing therapies, assuming any existing peripheral neuropathy is Grade 2 or less.
  • NSCLC
  • HNSCC
  • CC
  • GC and GEJ
  • EC
  • TNBC

B. Dose Optimization (Monotherapy and Combination Arms):

  • Limited to participants who have RR la/mUC,
  • Participants may have had up to 2 prior MMAE-containing therapies, assuming any existing peripheral neuropathy is Grade 2 or less 2. Participants must have per (RECIST) v1.1.

    3. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. For Nectin-4 targeted agents (approved or )

    • > one prior Nectin-4 targeted agents
  2. Peripheral neuropathy > Grade 2
  3. Participants with a history of, or with active, inflammatory skin disease, such as eczema, psoriasis that required or currently require biologics or oral to control disease are ineligible.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
149 participants (estimated)

Study arms

  • Experimental
    Single Agent Dose Level 1

    Single Agent Dose Level 1

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 2

    Single Agent Dose Level 2

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 3

    Single Agent Dose Level 3

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 4

    Single Agent Dose Level 4

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 5

    Single Agent Dose Level 5

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 6

    Single Agent Dose Level 6

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 7

    Single Agent Dose Level 7

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 8

    Single Agent Dose Level 8

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Level 9

    Single Agent Dose Level 9

    Drug: RNDO-564

  • Experimental
    Combination Dose Escalation- Dose Level 1

    Combination Dose Escalation- Dose Level 1

    Drug: RNDO-564 · Drug: Pembrolizumab

  • Experimental
    Combination Dose Escalation - Dose Level 2

    Combination Dose Escalation - Dose Level 2

    Drug: RNDO-564 · Drug: Pembrolizumab

  • Experimental
    Single Agent Dose Optimization - Dose Level 1

    Single Agent Dose Optimization - Dose Level 1

    Drug: RNDO-564

  • Experimental
    Single Agent Dose Optimization - Dose Level 2

    Single Agent Dose Optimization - Dose Level 2

    Drug: RNDO-564

  • Experimental
    Combination Dose Optimization - Dose Level 1

    Combination Dose Optimization - Dose Level 1

    Drug: RNDO-564 · Drug: Pembrolizumab

  • Experimental
    Combination Dose Optimization- Dose Level 2

    Combination Dose Optimization - Dose Level 2

    Drug: RNDO-564 · Drug: Pembrolizumab

Interventions

  • DrugRNDO-564

    CD28 x Nectin-4 bispecific

  • Anti-PD-1 therapy

06

What researchers measure

Primary outcomes

  1. All Arms: - Proportion of participants with adverse events (including dose limiting toxicities) as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0

    • Type, frequency, and severity of adverse events (AEs)

    Time frame: From Day 1 to 90-days post last dose

  2. Dose Optimization Arms: • Identify one or more recommended Phase 2 doses (RP2D)

    To evaluate the totality of data

    Time frame: From Day 1 up to 24 months

Secondary outcomes

  1. All Arms: To evaluate serum concentrations at specified timepoints of RNDO-564 as a single agent or in combination with pembrolizumab

    Time frame: From Day 1 up to 25 months (inclusive of 30 day safety follow-up)

  2. All Arms: Proportion of participants that develop anti-drug antibodies to RNDO-564

    Time frame: Baseline (predose) up to 25 months (inclusive of 30 day safety follow-up)

  3. All Arms: Evaluate the prevalence, incidence and impact of anti-drug antibodies to RNDO-564

    Time frame: From Baseline (predose) up to 25 months (inclusive of the 30 day safety follow-up).

  4. All Arms: Objective Response Rate Among Participants

    Time frame: percentage of participants from Day 1 until the date of the first documented partial response or complete response assessed up to 24 months

  5. All Arms: Duration of Response

    Time frame: Time between the first partial response or complete response and the date of first documented progression or date of death, whichever came first, assessed up to 24 months

  6. All Arms: Median Progression Free Survival Time Among Participants

    Time frame: The number of months from Day 1 until the date of first documented progression or date of death, whichever came first, assessed up to 24 months

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2029, 39 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 39 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 20, 2025
StartActual
Nov 17, 2025
Primary completionEst.
Feb 28, 2029
CompletionEst.
Mar 31, 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07218003
Lead sponsor
Rondo Therapeutics
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Nov 17, 2025
Primary completion
Feb 28, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Thomas Manley, MD
study director · Rondo Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion